|会社名||Bausch Health Companies Inc （BHC ボシュ・ヘルス・カンパニ―ズ）|
|業種||医薬品 医療関連（Health Care）|
|概要||事業概要 バウシュ・ヘルス・カンパニズ(Bausch Health Companies Inc)(旧名：Valeant Pharmaceuticals International Inc)は医薬品、医療機器および市販商品を開発、製造、販売するカナダ会社である。同社は主に目の健康、消化器、皮膚科の治療分野で製品を開発する。皮膚科製品は光線性角化症、座瘡、アトピー性皮膚炎、乾癬および他の皮膚病を治療する。また、顔のしわ、にきび、色素沈着、レーザー脱毛などの症状に対応する美容医療機器の選択肢も提供する。胃腸（GI）セグメントはGIおよび肝性脳症、下痢および潰瘍性大腸炎を伴う過敏性腸症候群を含む肝臓病態を治療する製品を提供する。目の健康製品は、コンタクトレンズ、医薬品および外科などのカテゴリーで販売される。 バレアント・ファ―マシュ―ティカルズ・インタ―ナショナルは、カナダの医薬品・医療機器メ―カ―。医薬品、市販薬、コンタクトレンズ・眼内レンズ・眼科手術用機器を含む医療機器の開発、製造、販売に従事する。事業は、市場開発と新興成長市場に分かれ、米国、プエルトリコ、カナダ、ポ―ランド、ロシアで販売する。 Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.|
|代表者氏名||Joseph C. Papa|
|代表者役職名||Chairman of the Board Chief Executive Officer|
|決算概要||決算概要 BRIEF: For the fiscal year ended 31 December 2018 Bausch Health Companies Inc revenues decreased 4% to $8.38B. Net loss before extraordinary items totaled $4.15B vs. income of $1.43B. Revenues reflect Bausch + Lomb / International segment decrease of 4% to $4.66B U.S. Diversified Products segment decrease of 3% to $1.34B United States and Puerto Rico segment decrease of 4% to $5.01B Other Foreign Countries segment decrease of 11% to $1.04B.|
TSX Whimpers to End Week 2022/05/06 20:23:00 Baystreet Canada
Stocks ended a nightmare week with more loss spread over a broad base of stocks. The S&P/TSX Composite finished lower Friday 62.89 points to 20,633.28, the decline on the week being 129 points, or 0.62%. The Canadian dollar skidded 0.37 cents at 77.59 cents U.S. Techs suffered the hardest blows, with Shopify wounded $39.57, or 7.5%, to $490.06, while Dye & Durham lost $1.21, or 6.6%, to $17.27. In the real-estate sector, Tricon Capital fell 40 cents, or 2.4%, to $16.62, while Granite REIT subtracted $2.53, or 2.8%, to $86.93. Health-care stocks also too their knocks, with Bausch Health off 89 cents, or 4.1%, to $20.62, while Aurora Cannabis slid 12 cents, or 3.2%, to $3.61. Utilities tried to restore some balance, with Transalta Renewables gaining 34 cents, or 2.4%, to $14.11, while Fortis added $1.35, or 2.2%, to $63.01. In communications, TELUS jumped 70 cents, or 2.2%, to $32.33, while Shaw picked up 52 cents, or 1.4%, to $37.58. On the economic slate, Statistics Canada revealed employment was little changed in April after two consecutive months of growth.
Why Cramer Recommends Buying Marvell Technology 2022/05/05 11:40:20 Benzinga
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Accenture plc (NYSE: ACN ) had a great quarter. He recommended buying the stock. Cramer said there is too much risk in Manulife Financial Corporation (NYSE: MFC ). When asked about Bausch Health Companies Inc. (NYSE: BHC ), Cramer said, "We wanted to buy more today, but we ran out of time. … Full story available on Benzinga.com
Cramer’s lightning round: Marvell Technology and Bausch Health are buys 2022/05/04 23:32:34 Newslanes
Bausch Health: “We wanted to buy more today, but we ran out of time. This thing is being put on sale. There are shorts taking it all the way down. It is quite ridiculous. I wanted to be able to buy a huge slug of it today, so that’s how I feel for the [Charitable […] Cramer’s lightning round: Marvell Technology and Bausch Health are buys
Cramer''s lightning round: Marvell Technology and Bausch Health are buys 2022/05/04 22:53:23 CNBC
"Mad Money" host Jim Cramer rings the lightning round bell, which means he''s giving his answers to callers'' stock questions at rapid speed.
Bausch Health Companies Inc. (BHC) CEO Joe Papa Presents at Cowen 42nd Annual Healthcare Conference (Transcript) 2022/03/08 21:27:08 Seeking Alpha
Friday, Feb. 25, 2022: Jim Cramer on selling some Chevron for growth stock buying opportunities 2022/02/25 15:55:21 CNBC
Jim Cramer and Jeff Marks break down recent market movements reflecting Russia-Ukraine developments. They explain why they sold some Chevron shares and bought growth stocks including Qualcomm, Morgan Stanley, Eli Lilly, Wells Fargo, and Bausch Health. They also take a deep dive into why they''re watching PayPal, Google, and Linde.
New Study from StrategyR Highlights a $15.8 Billion Global Market for Contact Lenses by 2026 2022/02/24 16:05:00 Benzinga
SAN FRANCISCO , Feb. 24, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Contact Lenses - Global Market Trajectory & Analytics" . The report presents fresh perspectives on opportunities and challenges in a significantly transformed post COVID-19 marketplace. FACTS AT A GLANCE What''s New for 2022? Global competitiveness and key competitor percentage market shares Market presence across multiple geographies - Strong/Active/Niche/Trivial Online interactive peer-to-peer collaborative bespoke updates Access to our digital archives and MarketGlass Research Platform Complimentary updates for one year Edition: 18; Released: February 2022 Executive Pool: 5714 Companies: 94 - Players covered include Alcon, Inc.; Bausch Health Companies, Inc.; CooperVision, Inc.; Ginko International Co., Ltd.; Johnson & Johnson Vision Care, Inc.; Menicon Co., Ltd; St. Shine Optical Co., Ltd. and Others.
Bausch Health Companies Inc. (BHC) CEO Joseph Papa on Q4 2021 Results - Earnings Call Transcript 2022/02/23 19:02:11 Seeking Alpha
Investing Club: We''re looking past Bausch''s mixed quarter to the greater value a breakup brings 2022/02/23 18:10:59 CNBC
The upcoming Bausch + Lomb and Solta Medical IPOs are key to realizing upside earnings power locked away in the bigger company.
Ophthalmic Drugs Market Impressive Gains including key players- Aerie Pharmaceuticals Inc., Abbive (Allergan), Bausch Health, Bayer AG, F. Hoffmann-La Roche Ltd 2021/07/17 15:11:51 OpenPR
Latest released, the research study on Global Ophthalmic Drugs Market Report Forecast 2021 - 2025, offers a detailed overview of the factors influencing the global business scope. Ophthalmic Drugs Market research report shows the latest market insights, current situation analysis
Parkinsons Disease Treatment Market: Latest Industry Key Players GlaxoSmithKline Plc, Merck KGaA, Novartis AG, Bausch Health, AbbVie Inc. 2021/07/15 15:35:56 OpenPR
Parkinsons disease is one of the progressive nervous system disorder that affects the movement of individuals. The symptoms of Parkinsons starts gradually with a barely noticeable tremors in one hand. The further symptoms of the disease usually leads to stiffness,
Macular Degeneration Treatment Market 2021 Status and Prospect- F. Hoffmann-La Roche Ltd., Novartis AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., and Pfizer Inc. 2021/07/15 07:03:32 OpenPR
The Macular Degeneration Treatment Market report is an in-depth study of the market, along with an analysis of its key segments. The relationship is built through extensive primary and secondary research. In-depth market data is generated through interviews and data collection
Cystinuria Market: Industry Analysis, Treatment, Pipeline Drugs and Key Companies By DelveInsight| Bausch Health, Mission Pharmacal, Retrophin, Advicenne and Many Others 2021/07/14 21:46:01 AB Newswire
Hirsutism Market 2021 Precise Outlook Allergan PLC, Ajanta Pharma, Alpaya Dermaceuticals, Nisim Inc., Wet and Dry Personal Care, Bausch Health Companies Inc. 2021/07/14 11:33:21 OpenPR
Hirsutism Market Research Report provides detailed analysis of Growth Factors of the market as well as it gives analysis of the Market size, Latest trends, SWOT Analysis by Regions and Forecasted market research data until 2025. The Hirsutism market report has studied key opportunities
関連キーワード （医薬品 米国株 BHC ボシュ・ヘルス・カンパニ―ズ BHC ）